Quick Summary
Covering the latest research from top Wall Street investment banks

China Vanke's FY25 results missed expectations on impairments; Goldman Sachs maintains Sell

Institution
Goldman Sachs
Date
2026-04-03
Authors
Yi Wang, CFA, Shi Xu, Kaiyan Jing
Company
China Vanke
Ticker
000002.SZ
Industry
China Property
Rating
Sell
BearishLow confidenceFY25 loss came in worse than expected, impairment was sizeable, and visibility on sales and deliveries is weakening while leverage and short-term debt pressure are rising.
AuthorsYi Wang, CFA, Shi Xu, Kaiyan Jing
Target priceRmb3.9
Business segmentsProperty Development、Property Sales、Asset Revitalization and Disposal
Research firm divisions/subsidiariesGoldman Sachs(Other)

AI summary card

China Vanke's FY25 results missed expectations on impairments; Goldman Sachs maintains Sell

Goldman Sachs says Vanke's FY25 net loss widened mainly because of Rmb56bn in impairments; sales, revenue recognition and liquidity pressure are still worsening, and the 12-month target price was cut to Rmb3.9.

Rating: Sell; 12-month target price: Rmb3.9; current price: Rmb4.04; implied downside: 3.5%.
Results MissMaintain SellLiquidity PressureAsset ImpairmentProperty Development
  • FY25 net loss was Rmb88.6bn, worse than the company's prior warning of a Rmb82bn loss, with about 90% of the loss coming from impairments, higher-than-expected taxes and a larger loss from associates/joint ventures.
  • Rmb14.7bn of public debt matures in 2026, of which Rmb11.3bn falls between April and July 2026, implying elevated near-term debt service pressure.
  • Goldman Sachs cut its 2026E-2028E net loss forecasts to Rmb13.6bn/Rmb12.1bn/Rmb11.3bn and lowered Vanke's A/H target prices by 13%/14% to Rmb3.9/HK$3.0.

Report interpretation

Overview

This report is Goldman Sachs' commentary on China Vanke's FY25 results. The report says the company's 2025 performance was weaker than expected, with the main reasons being large inventory and related asset impairments, while slower sales, lower unsettled resources, shrinking delivery scale and debt maturity pressure together are reducing visibility on future earnings and cash flow. Goldman Sachs maintains its Sell rating on Vanke A/H shares.

Core views

The key views are as follows: first, FY25 net loss was Rmb88.6bn, mainly driven by Rmb56bn of impairments, including Rmb41bn booked in 4Q25. Second, the sales outlook remains weak, with 3M26 sales down 53% year on year to Rmb17bn; new starts and saleable resources are constrained and there is no incremental land bank. Third, the balance sheet continues to deteriorate, with gross leverage, net gearing and the cash-to-short-term debt ratio all indicating rising liquidity pressure. Fourth, although 4Q25 gross margin stayed at 5.8% and inventory impairment coverage is gradually moving closer to the peer average, lower average selling prices on contracted but undelivered sales suggest further downside risk to gross margins.

Analysis framework

The report mainly compares actual results with Goldman Sachs' prior forecasts, Wind consensus estimates and peer coverage averages, and evaluates the investment case for China Vanke A/H shares based on NAV discount, P/B valuation, sales absorption, unsettled resources, delivery plans, leverage metrics and debt maturity profile.

Methodology notes

  • Valuation methodNAV discount valuation

    12-month target price based on 2026E year-end NAV discount

    China Vanke's A-share target price of Rmb3.9 is based on a 10% discount to 2026E year-end NAV; China Vanke's H-share target price of HK$3.0 is based on a 35% discount to 2026E year-end NAV.

  • Risk and factor analysisGS Factor Profile

    growth, financial returns, valuation multiples and composite percentile

    Goldman Sachs uses its factor framework to compare a stock's growth, return and valuation attributes relative to the market and sector peers.

  • Event probability frameworkM&A Rank

    M&A probability score

    The report discloses Vanke's M&A Rank as 3, indicating a low probability of being acquired and usually not included in the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

  • China Vanke (A) 000002.SZ
    Core coverage name
    Strengths
    4Q25 gross margin remained stable, asset revitalization and disposal accelerated somewhat, and inventory provision coverage is gradually moving closer to the peer average.
    Weaknesses
    FY25 loss missed expectations, visibility on sales and revenue recognition is declining, leverage metrics are deteriorating, and short-term debt pressure is high.
    Comparison
    Currently trades at about a 6% discount to 2026E NAV and 0.5x 2026E P/B; Goldman Sachs' mainland property coverage averages a 23% discount to NAV and 0.4x P/B.
    Risks
    If government financing support, asset disposals or sales recovery in higher-tier cities are better than expected, the share price could rise.
  • China Vanke (H) 2202.HK
    Same-company H-share covered name
    Strengths
    Target price is based on a larger NAV discount, and the current valuation already reflects some of the pressure.
    Weaknesses
    Shares the same fundamental pressures as the A share, including slower sales, weaker profitability and liquidity pressure.
    Comparison
    Currently trades at about a 36% discount to 2026E NAV and 0.3x 2026E P/B; Goldman Sachs' offshore coverage average is a 35% discount to NAV and 0.5x P/B.
    Risks
    Financing support, asset sales, refinancing progress or a recovery in industry demand could improve market expectations.

Key data

  • FY25 net lossRmb88.6bnWorse than the company's prior warning of a Rmb82bn loss, mainly driven by impairments, taxes and losses from associates/joint ventures.
  • FY25 impairment chargesRmb56bnOf which Rmb41bn was booked in 4Q25.
  • 2026 public debt maturitiesRmb14.7bnOf which Rmb11.3bn matures between Apr and Jul 2026.
  • 3M26 salesRmb17bn, -53% YoYWeaker than peers under coverage and top 100 developers.
  • FY25 revenueRmb231.3bn, -32% YoY19% below Wind consensus.
  • FY25 gross margin5.5%Up 0.6ppt YoY and 0.7ppt above Goldman Sachs' prior forecast.
  • Net gearing112%Up 21ppt QoQ and 30ppt YoY.
  • Cash/short-term debt ratio38%Down 14ppt YoY, indicating an insufficient near-term liquidity buffer.
  • China Vanke A target priceRmb3.9Down 13% from prior, implying about 3.5% downside.
  • China Vanke H target priceHK$3.0Down 14% from prior, implying about 0.7% upside.

Impact & implications

The report's investment implication for Vanke is negative: in the short term, the large impairment brings inventory provisions closer to the peer average, but it does not remove the pressure from declining sales, shrinking deliveries and cash flow. Over the medium term, if contracted sales remain weak, unsettled resources continue to decline and shareholder support weakens at the margin, visibility on deleveraging and valuation recovery remains limited.

Risks

  • The government provides more comprehensive and targeted financing support.
  • Asset disposals and refinancing plans are executed better than expected, driving debt down.
  • The real estate market in higher-tier cities recovers more strongly than expected, supporting inventory absorption and ASP improvement.
  • If debt negotiations or shareholder support fall short of expectations, liquidity pressure could intensify further.
  • Continued declines in unsettled sales ASP could prolong pressure on gross margin and impairments.

What to watch

  • Repayment or extension arrangements for the Rmb11.3bn of public debt maturing between April and July 2026.
  • The scale of follow-on funding support for Vanke from SZMC and other shareholders and creditors.
  • Trends in 2026 contract sales, absorption rates and ASP.
  • Progress on asset revitalization, asset disposals and exits from non-core cities.
  • Whether deliveries can proceed on schedule and stabilize operating cash flow.
Zhejiang ICP No. 2022035445-5
Disclaimer: Market data, charts, indicators, research views, and other information provided on this website are intended solely for information display, research communication, and educational reference. They should not be regarded as personalized investment advice, securities recommendations, trading instructions, solicitations, or guarantees of return. While we strive to improve the reliability of our data and content, such information may still be subject to delays, errors, incompleteness, or untimely updates due to source differences, methodological limitations, system processing, or market volatility. Users should exercise independent judgment based on their own circumstances and bear all risks and responsibilities arising from the use of this website.

Settings

Sign in to view recent logins